利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

452 条记录 (耗时 0.026 秒)

    BIOSENSORS FOR MONITORING BIOMOLECULE LOCALIZATION AND TRAFFICKING IN CELLS
    98.
    发明公开
    BIOSENSORS FOR MONITORING BIOMOLECULE LOCALIZATION AND TRAFFICKING IN CELLS 审中-公开
    生物传感器监测细胞生物分子的定位和交通

    公开(公告)号：EP3194960A1

    公开(公告)日：2017-07-26

    申请号：EP15841561.2

    申请日：2015-09-21

    申请人： The Royal Institution for the Advancement of Learning / McGill University ,  Université de Montréal

    发明人： LAPORTE, Stéphane Alain ,  NAMKUNG, Yoon ,  BOUVIER, Michel ,  LE GOUILL, Christian ,  HOGUE, Mireille ,  LUKASHEVA, Viktoriya ,  KOBAYASHI, Hiroyuki ,  DEBLOIS, Denis ,  DURETTE, Etienne

    IPC分类号： G01N33/53 ,  C12M1/34 ,  C12N15/62 ,  C12Q1/02 ,  C12Q1/66 ,  G01N33/58

    CPC分类号： C07K14/723 ,  C07K2319/60 ,  G01N33/5035

    摘要： Bioluminescence resonance energy transfer (BRET) biosensors for assessing the intracellular localization, internalization and trafficking into cellular compartments of proteins such as receptors, and other biomolecules such as second messengers, are disclosed. These biosensors, which are dependent on the concentration/density of the BRET donor and acceptor in cellular compartments rather that specific protein-protein interactions, use a Renilla GFP/Luc BRET pair, which allows the robust and reproducible monitoring of protein trafficking/localization, with a sensitivity compatible with high-throughput screening (HTS). The use of these biosensors for various applications, including assessing/monitoring protein endocytosis, recycling and intra-cellular trafficking, receptor maturation/rescue by pharmacological chaperones, various endocytosis/exocytosis processes, activation/inhibition, as well as biomolecule concentration/density in different cellular compartments, is also disclosed.

    摘要翻译： 公开了生物发光共振能量转移（BRET）生物传感器，用于评估细胞内定位，内化和运输到蛋白质如受体和其他生物分子如第二信使的细胞区室中。 这些生物传感器依赖于细胞区室中BRET供体和受体的浓度/密度而非特定的蛋白质 - 蛋白质相互作用，使用Renilla GFP / Luc BRET对，其允许对蛋白质运输/定位的稳健和可重现的监测， 灵敏度与高通量筛选（HTS）兼容。 将这些生物传感器用于各种应用，包括评估/监测蛋白质内吞作用，再循环和细胞内运输，通过药理学分子伴侣的受体成熟/拯救，各种内吞作用/胞吐作用过程，活化/抑制以及不同细胞区室中的生物分子浓度/密度 ，也被披露。

    VISION STRENGTHENING METHODS AND SYSTEMS
    99.
    发明公开
    VISION STRENGTHENING METHODS AND SYSTEMS 审中-公开
    视觉强化方法和系统

    公开(公告)号：EP3185746A1

    公开(公告)日：2017-07-05

    申请号：EP15837049.4

    申请日：2015-08-27

    申请人： The Royal Institution for the Advancement of Learning / McGill University

    发明人： HESS, Robert F. ,  FARIVAR-MOHSENI, Reza ,  REYNAUD, Alexandre

    IPC分类号： A61B3/08 ,  A61H5/00

    CPC分类号： A61F9/00829 ,  A61B3/08 ,  A61F9/008 ,  A61F9/022 ,  A61F2009/00846 ,  A61H5/00 ,  A61H2201/165 ,  A61H2201/5007 ,  A61H2201/5043 ,  A61H2201/5097

    摘要： Active dichoptic perceptual-learning tasks or dichoptic game play have been shown to significantly improve visual acuity of amblyopic children and adults. However, these dichoptic perceptual learning tasks are intensive and repetitive such that non-compliance is high. In contrast, the invention provides dichoptic perceptual learning in a manner that the user maintains its use and compliance is increased. Further, compliance becomes automatic if the user performs tasks in a normal manner and “forgets” that they are actually undergoing treatment as it is integrated with minimal disruption to their life and activities. Accordingly, a methodology exploiting complementary dichoptic stimulation is presented.

    摘要翻译： 主动分光感知学习任务或分光游戏已显示显着改善弱视儿童和成人的视力。 然而，这些dichoptic知觉学习任务是密集的和重复的，因此不遵从性很高。 相反，本发明以用户维持其使用并且遵从性增加的方式提供了分光学感知学习。 此外，如果用户以正常方式执行任务并且“忘记”他们实际上正在接受治疗，则遵从性变为自动，因为它被整合在对他们的生活和活动的最小破坏中。 因此，提出了一种利用补充分光刺激的方法。

    INTRAOCULAR PRESSURE-REGULATED EARLY GENES AND USES THEREOF
    100.
    发明授权
    INTRAOCULAR PRESSURE-REGULATED EARLY GENES AND USES THEREOF 有权
    弗吉尼亚州麻省理工学院ZWISCHENAUGENDRUCK UND VERWENDUNGEN DAVON

    公开(公告)号：EP1957986B1

    公开(公告)日：2017-05-24

    申请号：EP06844496.7

    申请日：2006-11-22

    申请人： McGill University

    发明人： SARAGOVI, H., Uri

    IPC分类号： G01N33/574 ,  C07K16/30 ,  C12N15/12 ,  C07K14/705 ,  A61K31/7088

    CPC分类号： C07K16/18 ,  A61K2039/505 ,  C07K14/47 ,  C07K16/30 ,  C07K2317/76 ,  G01N33/5308 ,  G01N2800/168

    摘要： The present invention relates to methods to treat glaucoma and glaucoma-related conditions through the regulation of changes in gene expression that are mediated by high intraocular pressure or alpha2 macroglobulin administration. Glaucoma, retinal ganglion cell (RGC) death and chronic ocular hypertension are treated using pharmaceutical compositions which comprise substances that inhibit the expression or activity of intraocular pressure-regulated early genes (IPREGs) or their gene products that are up-regulated by high intraocular pressure or alpha2 macroglobulin administration and/or which increase the expression or activity of IPREGs or their gene products that are down-regulated by high intraocular pressure or alpha2 macroglobulin administration. The invention also relates to methods of identifying an IPREG and methods to test for chronic ocular degeneration and the onset of RGC stress in an individual by measuring the expression level of IPREG proteins.

    摘要翻译： 本发明涉及通过调节由高眼内压或α2巨球蛋白给药介导的基因表达变化来治疗青光眼和青光眼相关病症的方法。 使用药物组合物治疗青光眼，视网膜神经节细胞（RGC）死亡和慢性高眼压症，其包含抑制眼内压调节早期基因（IPREG）或其高眼内压上调的基因产物的表达或活性的物质 或α2巨球蛋白施用和/或增加由高眼内压或α2巨球蛋白施用而下调的IPREG或其基因产物的表达或活性。 本发明还涉及通过测量IPREG蛋白的表达水平来鉴定IPREG的方法和测试个体中慢性眼变性和RGC应激发作的方法。